Epic Sciences' chief scientific officer named leading global thinker by Foreign Policy magazine.
Epic Sciences' Chief Scientific Officer Dena Marrinucci, Ph.D., was named today by Foreign Policy magazine as one of this year’s 100 Leading Global Thinkers. Marrinucci will be honored at a gala in Washington, D.C. this evening.
Epic Sciences partners with University of Pennsylvania's Abramson Cancer Center on cancer therapy discoveries through liquid biopsy.
Epic Sciences, Inc. announced today a collaboration with the Abramson Cancer Center of the University of Pennsylvania (Penn) on multiple studies to explore biomarkers, identified by analysis of circulating tumor cells (CTCs) at a single cell resolution, that are predictive of response to personalized cancer therapeutics.
Circulating tumor cells (CTC) in patients' blood detected by Epic Sciences are an "accurate representation" of genetic aberrations found in fresh metastatic tumor samples.
Most men with advanced prostate cancer, whether initially treated through surgical or chemical castration, eventually develop drug-resistant tumors. Monitoring for drug resistant genetic mutations could inform selection of the next line of therapy. A new non-invasive approach developed by Epic Sciences may be as effective at biomarker characterization as invasive surgical biopsies for metastatic castration-resistant prostate cancer (mCRPC) patients.
Epic Sciences' platform capable of single cell CTC identification sequencing in late stage, metastatic cancer.
After successive cancer therapies, multiple subpopulations of cancer cells arise, each with divergent genetic aberrations that may confer drug resistance or susceptibility. Tissue biopsies may not detect these subpopulations, but a liquid biopsy of blood using Epic Sciences’ no cell left behind® technology may help identify these important tumor cells and characterize how a patient’s tumors have evolved over time.
Epic Sciences to present at World CDx Boston 2015.
Epic Sciences, Inc. announced today that Murali Prahalad, Ph.D., president and CEO, is scheduled to present at the World CDx Boston 2015, taking place at the Hilton Boston Logan Airport, September 8 – 11, 2015.
Epic Sciences appoints Dave Henderson as chief information officer.
Epic Sciences, Inc. announced today the appointment of Dave Henderson as Epic Sciences’ chief information officer (CIO). Mr. Henderson has more than 20 years of experience in information technologies at companies including Sequenom, Inc., CBS Corporation, and Paramount Pictures Corporation.
Epic Sciences' Dr. Dena Marrinucci is recognized as an honoree of MIT Technology Review's annual Innovators Under 35 list.
Today, MIT Technology Review revealed its annual list of Innovators Under 35, which includes Epic Sciences' Dena Marrinucci, Ph.D., who has been recognized for her groundbreaking work in developing and advancing a new technology to unlock the promise of using a simple blood test, called a liquid biopsy, to manage cancer treatments.